A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 30 Mar 2015
At a glance
- Drugs KD 018 (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 26 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 May 2009 Planned end date changed from 1 Mar 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.